Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Receivables - Other (2022 - 2025)

Historic Receivables - Other for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $2.6 million.

  • Taysha Gene Therapies' Receivables - Other changed 0.0% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.6 million for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Taysha Gene Therapies reported Receivables - Other of $2.6 million as of Q3 2025, which was down 0.0% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Receivables - Other peaked at $2.6 million during Q1 2022, and registered a low of $2.6 million during Q1 2022.
  • In the last 4 years, Taysha Gene Therapies' Receivables - Other had a median value of $2.6 million in 2022 and averaged $2.6 million.
  • Data for Taysha Gene Therapies' Receivables - Other shows a peak YoY increase of 0.0% (in 2023) and a maximum YoY decrease of 0.0% (in 2023) over the last 5 years.
  • Over the past 4 years, Taysha Gene Therapies' Receivables - Other (Quarter) stood at $2.6 million in 2022, then changed by 0.0% to $2.6 million in 2023, then changed by 0.0% to $2.6 million in 2024, then changed by 0.0% to $2.6 million in 2025.
  • Its Receivables - Other stands at $2.6 million for Q3 2025, versus $2.6 million for Q2 2025 and $2.6 million for Q1 2025.